Ametris - formerly ActiGraph

Ametris - formerly ActiGraph Ametris is pioneering the digital transformation of clinical research

Digital health technologies are redefining oncology drug development by enabling continuous, objective data collection i...
04/06/2026

Digital health technologies are redefining oncology drug development by enabling continuous, objective data collection in real-world settings and bringing the patient experience to the center of trial design. From complex immunotherapies like CAR-T to conditions such as cancer pain and cachexia, DHTs support more patient-centric studies, smarter endpoints, and a faster path to better patient outcomes.

Explore our latest oncology resources page:
https://hubs.la/Q049Cz3r0

Digital health technologies have the potential to transform clinical trials, yet without careful planning and operationa...
03/26/2026

Digital health technologies have the potential to transform clinical trials, yet without careful planning and operational support, their implementation can create complexity, increase site burden, and influence data quality.

The Ametris Connect platform combines validated clinical sensors, state-of-the-art algorithms, ePRO and remote data capture solutions, and seamless study operations to power continuous, patient-focused data collection in modern digital clinical trials.

Check it out today: https://hubs.la/Q048vV290

Chronic insomnia disorder, marked by ongoing difficulty falling or staying asleep, can have a profound impact on health,...
03/19/2026

Chronic insomnia disorder, marked by ongoing difficulty falling or staying asleep, can have a profound impact on health, daily functioning, and overall quality of life. While cognitive behavioral therapy remains the gold-standard treatment, many patients with chronic insomnia rely on pharmacological options when symptoms persist.

This new case study by Ametris examines a randomized controlled trial to evaluate the effectiveness of a new therapy for chronic insomnia, highlighting how combining patient-reported and objective, real-world digital measures can deliver a more complete picture of treatment impact compared to conventional methods.

Read the full study: https://hubs.la/Q047BB_r0

Join us on Wednesday, March 25th for our next Digital Health Monthly webinar, Advancing Digital Measures from Scientific...
03/17/2026

Join us on Wednesday, March 25th for our next Digital Health Monthly webinar, Advancing Digital Measures from Scientific Rigor to Real-World Impact!

During the webinar, members of the Ametris Science Team will discuss some of the most impactful scientific insights, regulatory perspectives, and real-world DHT use cases shared at the recent ADDS 2026 scientific meeting in Atlanta.



Register at the link in the comments ⬇️

Traditional sleep assessments often stop when the sun comes up. But for patients with narcolepsy, IH, or chronic insomni...
03/13/2026

Traditional sleep assessments often stop when the sun comes up. But for patients with narcolepsy, IH, or chronic insomnia, Excessive Daytime Sleepiness (EDS) is a 24-hour burden that PSG and diaries frequently miss.

In our latest article, Matt Patterson, PhD, explores how continuous passive monitoring is closing the measurement gap in sleep disorder research.

Check out the full blog article in the comments ⬇️

Ametris and Signant Health are proud to announce a strategic partnership to advance drug development in central nervous ...
03/10/2026

Ametris and Signant Health are proud to announce a strategic partnership to advance drug development in central nervous system (CNS) disorders and other complex therapeutic areas. By integrating Ametris’ medical-grade wearable digital health technology with Signant Health’s industry-leading eCOA platform, this collaboration provides biopharma sponsors with a unified solution that combines clinician- and patient-reported outcomes with objective, continuous movement data.

This approach allows for a more complete view of patient function and treatment effects in conditions like Parkinson’s disease, Huntington's disease, and ALS, where capturing subtle changes between traditional assessment timepoints is critical for demonstrating meaningful clinical benefit.

Read the full announcement here: https://hubs.la/Q046bqHF0

Representatives from both Ametris and Signant Health will be at the AD/PD conference next week in Copenhagen. Contact us to schedule a meeting!

Across three days of discussion, ADDS 2026 brought together regulators, industry leaders, academic researchers, and tech...
03/09/2026

Across three days of discussion, ADDS 2026 brought together regulators, industry leaders, academic researchers, and technology developers to examine how digital health technologies (DHTs) are reshaping clinical research.

Join us on Wednesday, March 25th for a Digital Health Monthly webinar highlighting the most impactful scientific discussions, regulatory perspectives, and real-world use cases shared during the Ametris Digital Data Summit 2026!

📅 Wednesday, March 25
🕒 12:00 PM EST
Speakers: Christine Guo, Sylvain, and Michael P.

Register for the webinar here: https://hubs.la/Q0460XlS0

Ametris is heading to Medidata NEXT 2026 in New York City next week! Connect with us in advance and talk with Sarah Bell...
03/06/2026

Ametris is heading to Medidata NEXT 2026 in New York City next week! Connect with us in advance and talk with Sarah Bell and our newly appointed Chief Product Officer, Mandana Varahrami.

Don’t miss our Sensor Cloud booth session:
📍 Innovation Lounge Station
🕙 Tuesday, March 10th from 10:00 – 11:00 AM EST

Stop by to get a closer look at our integrated wearable solutions and discuss how our partnership can support your upcoming clinical trial.

Establishing clinical benefit is one of the most challenging and costly steps in developing new treatments for patients ...
03/04/2026

Establishing clinical benefit is one of the most challenging and costly steps in developing new treatments for patients with neuromuscular disorders (NMD) that are affected in physical activity, sleep, gait, and mobility.

Our updated Neuromuscular Disorder Digital Endpoint Guide offers guidance into how wearable Digital Health Technology can help clinical researchers unlock continuous, everyday insights.

Access the guide at the link in the comments below!

We're looking forward to connecting with the researchers and industry leaders at the Muscular Dystrophy Association’s Cl...
03/04/2026

We're looking forward to connecting with the researchers and industry leaders at the Muscular Dystrophy Association’s Clinical & Scientific Conference next week in Orlando!

Attending the conference? Connect with Sean Smith to discuss how Ametris is supporting advances in neuromuscular disease research. Whether you're refining study methodology or exploring innovative approaches to measurement and evidence generation, we’d welcome the conversation!

Schedule a meeting in advance: https://hubs.la/Q045Cxq70

Immunotherapies such as CAR-T are extending survival, yet reliance on inpatient monitoring for cytokine release syndrome...
03/03/2026

Immunotherapies such as CAR-T are extending survival, yet reliance on inpatient monitoring for cytokine release syndrome continues to restrict access.

In a new article, Christine Guo, PhD, Chief Scientific Officer at Ametris, explains how continuous digital monitoring and AI-driven analysis of physiological data can detect early CRS signals, support safer outpatient care, and help scale immunotherapy adoption.

Read the full perspective on the future of outpatient care in the comments ⬇️

This year’s ADDS 2026 Summit in Atlanta proved that research has moved past the "experimental" phase of wearables. We no...
02/27/2026

This year’s ADDS 2026 Summit in Atlanta proved that research has moved past the "experimental" phase of wearables. We now have a strong foundation showing what digital health technology and expansive data can achieve for scientific innovation and discovery.

Guided by leading experts and their work on shared foundation models, the industry is building a unified language for digital evidence, especially when it comes to and .

Address

Pensacola, FL

Opening Hours

Monday 8am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Telephone

+18503327900

Website

Alerts

Be the first to know and let us send you an email when Ametris - formerly ActiGraph posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Ametris - formerly ActiGraph:

Shortcuts

Featured

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category

About Us

ActiGraph's innovative and extensively validated physical activity and sleep monitoring solutions deliver accurate, measurable insights into the real world physiological behaviors of subjects involved in academic research, population health studies, and clinical trials. Trusted by researchers and scientists in more than 90 countries, ActiGraph hardware and software products are the most widely used and extensively validated objective activity monitoring technology available.